Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

DexCom reported revenues of $1.21 billion, up 21.6% year on year. This print exceeded analysts’ expectations by 2.5%. Overall, it was a strong quarter for the company with a solid beat of analysts’ ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Crypto liquidations continued their rout early morning Asia hours after the broader crypto market continued its plunge hours after U.S. President Donald Trump threatened 100% tariffs on Chinese ...

The Paramount and Skydance merger, which was announced in 2024, was officially completed in August 2025. The company’s Q3 ...

If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...

The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Dexcom, Inc. securities during the class period because the Company ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.